Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines, marking a significant move to strengthen Gilead’s position in inflammation and autoimmune disease research. The transaction brings gamgertamig, also known as OM336, into Gilead’s expanding inflammation portfolio and establishes it as a central asset for Lakefront’s clinical development strategy. The companies said the deal supports their shared ambition to advance T cell engager therapies for patients with severe antibody-mediated diseases where treatment options remain limited.
Strategic Importance of the Acquisition
The acquisition adds a clinical-stage BCMAxCD3 T cell engager designed to target plasma cells and B cells through a limited subcutaneous treatment course. Gamgertamig is being developed for autoimmune diseases including autoimmune hemolytic anemia and immune thrombocytopenia, both of which can involve serious complications and long-term treatment burden. By focusing on deep immune-cell depletion and potential durable disease control, the program reflects a broader industry shift toward therapies that may move beyond chronic symptom management.
Deal Terms and Development Responsibilities
Under the agreement, Gilead acquired all outstanding equity of Ouro Medicines for $1.675 billion, with the potential for up to $500 million in additional milestone payments. Gilead and Lakefront will equally share the upfront payment, subject to customary adjustments, as well as the possible contingent payments tied to future progress. Lakefront has acquired substantially all of Ouro’s team and operational assets and will lead ongoing and future Phase 1/2 clinical studies, while Gilead will take responsibility for registrational and later-stage development.
Commercial Rights and Pipeline Expansion
Gilead will retain sole worldwide commercialization rights to gamgertamig outside territories held by Keymed Biosciences, which originally licensed the program and retains rights in Greater China. Lakefront is expected to receive tiered royalties of 20% to 23% on net sales generated by Gilead, creating a long-term financial interest in the therapy’s potential success. The agreement also gives Lakefront rights to a preclinical portfolio of three additional autoimmune-focused programs, with Gilead holding opt-in rights for a 50/50 profit split after clinical proof of concept for $75 million per program.
Clinical Outlook and Regulatory Status
Gamgertamig has received both Fast Track and Orphan Drug Designation from the U.S. Food and Drug Administration for certain autoimmune disease indications. The therapy is currently in Phase 2 development and is expected to enter registrational studies as early as 2027, depending on clinical progress and regulatory alignment. For Gilead, the asset complements its existing expertise in immunology and cell therapy, while giving Lakefront a foundational program around which to build its research and development pipeline.
The completion of the Ouro Medicines acquisition gives Gilead and Lakefront a clearer path to advance a differentiated autoimmune disease program with potential relevance across multiple severe indications. For Gilead, the deal reinforces a long-term strategy of investing in science that could address unmet medical needs and reshape treatment approaches in inflammation. For Lakefront, the transaction provides a clinical-stage anchor asset, additional preclinical opportunities, and continued flexibility to pursue further strategic investments while maintaining a substantial cash position.